Core Scientific, Inc. current report, 20 June 2023

Full document

Core Scientific, Inc. Form 8-K Summary

Business Context and Reporting Period

Core Scientific, Inc. filed this Current Report on June 20, 2023, with the report signed on June 21, 2023. The filing concerns the Company’s ongoing Chapter 11 bankruptcy proceedings, initiated on December 21, 2022. The Company and its debtor affiliates continue operating as debtors-in-possession under the supervision of the U.S. Bankruptcy Court for the Southern District of Texas.

The Company’s common stock and warrants trade exclusively on the OTC Pink Marketplace under the symbols CORZQ and CRZWQ, respectively, since January 3, 2023.

Financial Metrics and Liquidity

This Form 8-K does not provide current-period revenue, profit, cash flow, margin, debt-balance, or liquidity figures. It references risks involving the Company’s liquidity, debtor-in-possession financing, accelerated debt obligations, and the ability to generate significant cash flows from operations.

Material Changes Versus the Prior Comparable Period

  • The Debtors filed a proposed Joint Chapter 11 Plan of Reorganization and related proposed Disclosure Statement on June 20, 2023.
  • The proposed restructuring plan was not supported by the Company’s key stakeholders as of the filing date, and the Company had not reached agreement with stakeholders on the material terms of the restructuring.
  • The proposed Disclosure Statement had been submitted for Bankruptcy Court approval but had not been approved as of the filing date.
  • The filing of the proposed plan and disclosure statement was not a solicitation of votes. Any solicitation would require Bankruptcy Court approval and compliance with applicable law.

Guidance, Outlook, Risks, and Unusual Items

Management intends to pursue the restructuring described in the proposed plan, but there is no assurance that the Bankruptcy Court will approve it or that the Company will successfully consummate the restructuring, emerge from Chapter 11, or do so on the proposed terms.

  • The proposed plan and disclosure statement may be amended or supplemented and should not be relied upon as final.
  • The Company continues discussions with key stakeholders, and the lack of stakeholder support creates material execution risk.
  • Risks include Bankruptcy Court rulings, third-party motions, the duration and effects of the Chapter 11 cases, increased legal and professional costs, adverse effects on liquidity and operations, and failure to finalize or satisfy conditions of replacement debtor-in-possession financing.
  • Additional risks include debt acceleration, OTC trading volatility, and the Company’s ability to generate sufficient operating cash flow.
  • Exhibits include the proposed plan, proposed disclosure statement, and a stakeholder presentation containing confidential-information materials.

Important Facts for Investors to Verify

  • Whether the Bankruptcy Court approves the proposed Disclosure Statement and subsequently confirms the proposed plan.
  • Whether the Company reaches agreement with key stakeholders and obtains their support.
  • The final terms, treatment of creditors and equity holders, and any dilution or cancellation of existing securities under the restructuring.
  • The status, terms, and funding conditions of replacement debtor-in-possession financing.
  • The Company’s current cash balance, operating cash flow, debt obligations, and liquidity, which are not quantified in this filing.
  • Whether and when Core Scientific emerges from Chapter 11 and whether its common stock and warrants retain meaningful value.